0%
Print report
Variant interpretation report

ATM c.6248G>C, p.Gly2083Ala

NM_000051.4:c.6248G>C NP_000042.3:p.(Gly2083Ala) Missense · exon 43 View identifiers
Classification
Uncertain significance

Variant description:

The ATM NM_000051.4:c.6248G>C (NP_000042.3:p.(Gly2083Ala)) missense variant has previously been reported in somatic cancers (COSMIC; COSV53733578, n = 1 time). Experimental evidence: Direct prime-editing classified c.6248G>C as Functional with High confidence and DeepATM_predicted=No. Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About ATM

ATM encodes a kinase that acts as a master controller of the cellular DNA damage response: it detects double-strand breaks and coordinates DNA repair, cell cycle arrest, or apoptosis through downstream targets including p53, BRCA1, and CHK2. Loss-of-function mutations in both copies of ATM cause ataxia telangiectasia, an autosomal recessive disorder characterized by neurological problems, immune deficiency, and cancer predisposition. ATM functions as a tumor suppressor: individuals with ataxia telangiectasia are prone to childhood lymphomas, leukemias, and breast cancer, while carriers of a single altered copy have increased risk of breast, pancreatic, prostate, and other cancers. Somatic ATM mutations also occur in lymphoid malignancies and solid tumors, and ATM-deficient cancers are often especially sensitive to DNA-damaging treatments.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is ClinGen ATM VCEP v1.6. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 1 Benign evidence criteria: 1
Pathogenic criteria applied · 1
PP3Supporting
PP3 · supporting

Met: SpliceAI max delta 0.463 meets the ATM VCEP PP3 threshold of >=0.2 for predicted splice impact in missense variants.

Benign criteria applied · 1
BS3Supporting
BS3 · supporting

Met at Supporting: direct prime-editing classified c.6248G>C as Functional with High confidence and DeepATM_predicted=No.

Recorded classification: Uncertain significance

VUS: PP3 (supporting) and BS3 (supporting) are applied, but neither criterion alone satisfies an ATM VCEP pathogenic or benign combination rule.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
4 / 1,612,182 alleles

gnomAD v4.1: 4 / 1,612,182 alleles. Recorded AF 2.48111e-06. Recorded homozygote count 0.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

No screenshot for this evidence
REVEL score
0.295 recorded score

Recorded REVEL score: 0.295. Refer to the recorded PP3/BP4 rationale for interpretation.

ClinVar submissions
5 reported laboratory submissions

5 Uncertain significance. ClinVar API review status: criteria provided, multiple submitters, no conflicts.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. ATM, a kinase involved in the DNA damage response, is mutated in various solid and hematologic malignancies.

COSMIC
Cancer Hotspots
Somatic evidence
1 recorded samples

This variant has previously been reported in somatic cancers (COSMIC; COSV53733578, n = 1 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under ClinGen ATM VCEP v1.6, with the data and sources behind each one.

28 criteria with recorded statuses: 2 met · 6 not met · 4 not assessed · 16 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

Among the requested codon, residue, and domain criteria, PS1 is not met because no same-amino-acid pathogenic comparator was identified and splicing was not ruled out; PM1, PM5, PP2, and BP1 are not applicable under the ATM VCEP's explicit instructions.

PS2, PM6, and BS4 are explicitly not applicable under the ATM VCEP v1.6 specification; PP1 is not assessed because no qualifying exact-variant segregation data are documented.

The exact VCEP-governed Table S1 row is a direct high-confidence prime-editing result classified as Functional, supporting BS3 at Supporting strength and not supporting PS3.

The separate approved-assay file was consulted as required but contains methodology calibration rather than a variant-specific result for this variant.

Only PS4 was potentially evaluable; it remains not_assessed because no reviewed source provides variant-specific case-control counts or an effect estimate for NM_000051.4:c.6248G>C.

PP4, PP5, BP5, and BP6 are not applicable under the ATM VCEP's own criterion-specific instructions.

Met · 2

PP3 SupportingVCEPMet: SpliceAI max delta 0.463 meets the ATM VCEP PP3 threshold of >=0.2 for predicted splice impact in missense variants. Details ▾Hide ▴
Reasoning

The variant is missense. The ATM VCEP PP3 rule permits either missense REVEL >.7333 or predicted splice impact by SpliceAI >=0.2 for missense variants. REVEL is 0.295 and therefore does not meet the missense path, but SpliceAI max delta is 0.463, which meets the VCEP splicing path. PP3 is met at Supporting strength from the splice prediction; the same SpliceAI result is not used to claim BP4 or BP7.

VCEP rule
* Missense: REVEL **>.7333** * Splicing: Predicted impact via splicing (SpliceAI **≥0.2**) for silent, missense/in-frame and for intronic variants outside of donor and acceptor 1,2 sites.
Evidence considered
  • SpliceAI Lookup for NM_000051.4:c.6248G>C: DS_AG=0.075, DS_AL=0.463, DS_DG=0.0, DS_DL=0.0; max delta score=0.463.
  • Local REVEL predictor lookup for NM_000051.4:c.6248G>C: REVEL=0.295, below the VCEP PP3 missense cutoff >.7333.
  • Sun et al. 2025 Supplementary Table S1, exact row ATM c.6248G>C / G2083A: missense; REVEL=0.295; Classification=Functional; Confidence=High; DeepATM_predicted=No. This table was consulted as the governing VCEP reference file, while the PP3 decision uses the VCEP-named REVEL and SpliceAI paths.
Sources
BS3 SupportingVCEPMet at Supporting: direct prime-editing classified c.6248G>C as Functional with High confidence and DeepATM_predicted=No. Details ▾Hide ▴
Reasoning

The exact Table S1 row for ATM NM_000051.4:c.6248G>C (p.Gly2083Ala; p.G2083A) reports Classification=Functional, Confidence=High, and DeepATM_predicted=No. Per the governing VCEP file rule, DeepATM_predicted=No with High confidence means the Classification is a direct prime-editing measurement, and Functional maps to BS3_Supporting. This is consistent with the VCEP BS3 Supporting rule for a variant rescuing either an ATM-specific feature or radiosensitivity. The approved-assay methodology file was searched for c.6248G>C, p.Gly2083Ala, and p.G2083A; no variant-specific entry was found there, so no additional approved-assay result is claimed.

VCEP rule
Use when a variant rescues EITHER an ATM specifc feature OR rescues radiosensitivity.
Evidence considered
  • Sun et al. 2025, Supplementary Table S1, exact row c.6248G>C / G2083A: Classification=Functional; Confidence=High; DeepATM_predicted=No; under the VCEP file rule this is direct prime-editing evidence and Functional maps to BS3_Supporting.
  • The VCEP CSPEC entry limits BS3 Supporting to rescue of either an ATM-specific feature or radiosensitivity; the Table S1 Functional result supports the rescue direction, while no approved-assay result is claimed from the methodology-only file.
  • The approved functional-assay calibration file was searched under c.6248G>C, p.Gly2083Ala, and p.G2083A; no variant-specific result was present.
Still missing
  • No variant-specific entry for c.6248G>C, p.Gly2083Ala, or p.G2083A was found in clingen_hbop_atm_supplementary_tables_1_and_2_v1.xlsx; that file is an assay-methodology calibration table, not a per-variant results table.
Sources

Not met · 6 · evaluated, threshold not reached

PS1 VCEPNot met: no same-amino-acid pathogenic comparator was identified, and SpliceAI max delta 0.463 does not rule out splicing. Details ▾Hide ▴
Reasoning

PS1 is not met. The ATM PS1 guide requires the same amino-acid change as a previously established pathogenic variant and requires splicing to be ruled out for both missense alterations. The governing ATM_PS1_1.6.pdf was searched for c.6248G>C, p.Gly2083Ala, and p.G2083A; no entry was found. The available paper extraction for PMID:33320972 reports a different substitution at the same codon, c.6248G>A, p.Gly2083Glu, classified as a VUS, not the same amino-acid change. SpliceAI maximum delta score is 0.463, so a splice defect has not been ruled out by the available evidence.

VCEP rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change • Missense: This rule may be applied only when a splice defect is ruled out for both alterations either by RNA analysis and/or in silico splice predictions
Evidence considered
  • ATM_PS1_1.6.pdf, page 1: searched c.6248G>C, p.Gly2083Ala, and p.G2083A; no matching variant entry was present.
  • ATM PS1 rule: same amino-acid change as a previously established pathogenic variant is required, with splicing ruled out for both missense alterations.
  • PMID:33320972, Table 5, Patient #3: reports ATM c.6248G>A, p.Gly2083Glu, not the assessed c.6248G>C, p.Gly2083Ala; the reported variant was a VUS.
  • SpliceAI result: maximum delta score 0.463 (DS_AL), so the required splice exclusion is not established.
Still missing
  • ATM_PS1_1.6.pdf was searched for c.6248G>C, p.Gly2083Ala, and p.G2083A; no entry for this variant was found.
  • No established pathogenic variant producing p.Gly2083Ala was identified in the available evidence.
  • No RNA result ruling out a splice defect for both alterations is available.
Sources
PS3 VCEPNot met: direct prime-editing classified c.6248G>C as Functional with High confidence, indicating rescue rather than failure of ATM-specific function. Details ▾Hide ▴
Reasoning

The exact Table S1 row for ATM NM_000051.4:c.6248G>C (p.Gly2083Ala; p.G2083A) reports Classification=Functional, Confidence=High, and DeepATM_predicted=No, identifying a direct prime-editing measurement rather than a computational prediction. This result supports rescue rather than failure of an ATM-specific function, so PS3 is not met under the VCEP rule. The approved-assay methodology file was searched for c.6248G>C, p.Gly2083Ala, and p.G2083A; no variant-specific entry was found there.

VCEP rule
Use when a variant fails to rescue an ATM specifc feature, only (e.g. phosphorylation of ATM-specific targets). Do not use for radiosensitivity-only as that is not a feature specific to ATM deficiency
Evidence considered
  • Sun et al. 2025, Supplementary Table S1, exact row c.6248G>C / G2083A: Classification=Functional; Confidence=High; DeepATM_predicted=No; the row is therefore a direct prime-editing measurement under the VCEP file rule.
  • The approved functional-assay calibration file was searched under c.6248G>C, p.Gly2083Ala, and p.G2083A; no variant-specific result was present.
Still missing
  • No variant-specific entry for c.6248G>C, p.Gly2083Ala, or p.G2083A was found in clingen_hbop_atm_supplementary_tables_1_and_2_v1.xlsx; that file is an assay-methodology calibration table, not a per-variant results table.
Sources
PM2 VCEPNot met: the highest gnomAD v4.1 subpopulation AF is 0.00160%, above 0.001%, and the variant also occurs in European non-Finnish individuals. Details ▾Hide ▴
Reasoning

The ATM VCEP applies PM2 at Supporting when the frequency is ≤0.001% in the gnomAD subpopulation with the highest frequency; its exception requires a frequency >0.001% to be n=1 in a single subpopulation and absent from every other subpopulation. gnomAD v4.1 shows the highest subpopulation frequency in Remaining individuals at 1.60241e-05 (0.00160%, 1/62,406 alleles), exceeding 0.001%, while the variant is also present in European non-Finnish individuals (3 alleles), so the single-subpopulation exception does not apply. PM2 is therefore not met.

VCEP rule
Frequency **≤.001%** in gnomAD subpopulation with the highest frequency Exception: If >0.001% but n=1 in a single subpopulation (not present in any other subpopulation), that is sufficiently rare and PM2\_supporting would apply.
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 PM2 rule: Frequency ≤0.001% in the gnomAD subpopulation with the highest frequency; the exception requires >0.001% but n=1 in a single subpopulation not present in any other subpopulation.
  • gnomAD v4.1 Remaining individuals: AF 1.6024100246771145e-05 (0.00160%), 1/62,406 alleles, homozygotes = 0; European non-Finnish: 3/1,179,168 alleles, AF 2.5441667345111128e-06.
Sources
BA1 VCEPNot met: gnomAD v4.1 grpmax FAF is 6.8e-07 (0.000068%), below the VCEP's >0.5% BA1 threshold. Details ▾Hide ▴
Reasoning

The ATM VCEP applies BA1 when the gnomAD group maximum filtering allele frequency is >0.5%. gnomAD v4.1 reports grpmax FAF 6.8e-07 (0.000068%), which is below 0.5%; therefore BA1 is not met.

VCEP rule
Grpmax Filtering AF **\>.5%** in gnomAD
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 BA1 rule: Grpmax Filtering AF >0.5% in gnomAD.
  • gnomAD v4.1: total AF 2.48111e-06; grpmax FAF 6.8e-07; 4/1,612,182 total alleles; homozygotes = 0.
Sources
BS1 VCEPNot met: gnomAD v4.1 grpmax FAF is 6.8e-07 (0.000068%), below the VCEP's >0.05% BS1 threshold. Details ▾Hide ▴
Reasoning

The ATM VCEP applies BS1 when the gnomAD group maximum filtering allele frequency is >0.05%. gnomAD v4.1 reports grpmax FAF 6.8e-07 (0.000068%), which is below 0.05%; therefore BS1 is not met.

VCEP rule
Grpmax Filtering AF **\>.05%** in gnomAD
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 BS1 rule: Grpmax Filtering AF >0.05% in gnomAD.
  • gnomAD v4.1: total AF 2.48111e-06; grpmax FAF 6.8e-07; 4/1,612,182 total alleles; homozygotes = 0.
Sources
BP4 VCEPNot met: REVEL 0.295 exceeds the <=0.249 BP4 cutoff and SpliceAI max delta 0.463 exceeds the <=0.1 no-impact cutoff. Details ▾Hide ▴
Reasoning

The variant is missense. The ATM VCEP BP4 rule permits REVEL <=.249 or no predicted splice impact by SpliceAI <=0.1. REVEL is 0.295, above the missense cutoff, and SpliceAI max delta is 0.463, above the no-impact cutoff. Neither VCEP BP4 path is met.

VCEP rule
* Missense: REVEL score **≤.249** * Splicing: No predicted impact via splicing (SpliceAI **≤0.1**).
Evidence considered
  • Local REVEL predictor lookup for NM_000051.4:c.6248G>C: REVEL=0.295, which is above the ATM VCEP BP4 missense threshold of <=.249.
  • SpliceAI Lookup for NM_000051.4:c.6248G>C: max delta score=0.463, which is above the ATM VCEP BP4 no-predicted-impact threshold of <=0.1.
  • Sun et al. 2025 Supplementary Table S1, exact row ATM c.6248G>C / G2083A: missense; REVEL=0.295; Classification=Functional; Confidence=High; DeepATM_predicted=No.
Sources

Not assessed · 4 · no assessment recorded

PS4 VCEPNot assessed: available studies report aggregate ATM missense associations, not variant-specific counts or an odds ratio for c.6248G>C. Details ▾Hide ▴
Reasoning

The ATM VCEP requires a variant-specific case-control study with p-value ≤.05 and either an odds ratio, hazard ratio, or relative risk ≥2 or a lower 95% CI ≥1.5. The reviewed case-control papers report only aggregate ATM rare-missense associations, not counts or estimates for NM_000051.4:c.6248G>C: Decker et al. report OR=1.18 (95% CI 0.99–1.40; p=0.073) for aggregate rare ATM missense variants, and Dorling et al. report aggregate ATM rare-missense associations (population-based OR=1.06, 95% CI 1.00–1.13; P=0.051). These gene-level results cannot be assigned to this variant, so the VCEP PS4 rule cannot be evaluated. The literature_pass packet has no ai_classified_papers; its PS4 candidate papers were checked where paper_extracts were available and none mentions the requested variant or provides variant-specific case-control data.

VCEP rule
Case-control studies; p-value ≤.05 **and** (Odds ratio, hazard ratio, or relative risk ≥2 **or** lower 95% CI ≥1.5).
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 PS4 rule: Case-control studies; p-value ≤.05 and (Odds ratio, hazard ratio, or relative risk ≥2 or lower 95% CI ≥1.5).
  • Decker et al. 2017, PMID:28779002, Results, Risk associations for subsets of missense variants: aggregate rare ATM missense variants had OR=1.18, 95% CI 0.99–1.40, p=0.073 in 13,087 breast cancer cases and 5,488 controls; the paper does not mention c.6248G>C or p.Gly2083Ala.
  • Dorling et al. 2021, PMID:33471991, Results/Table 2/Tables S13 and S16/Figure S1C: aggregate rare ATM missense analysis in 60,466 cases and 53,461 controls reported population-based OR=1.06, 95% CI 1.00–1.13, P=0.051; the paper does not mention c.6248G>C or p.Gly2083Ala.
  • PMID:24418350 discusses ataxia-telangiectasia generally but does not mention the requested variant or provide variant-specific case-control data.
  • PMID:25394175 does not mention ATM c.6248G>C or p.Gly2083Ala and provides no variant-specific case-control data.
  • literature_pass.json ai_classified_papers is empty; PS4 candidate PMID:20301317 and PMID:20301790 have no fetched paper extraction available for variant verification.
Still missing
  • A variant-specific affected-case and control comparison, or matched-ancestry control frequency with sufficient counts, is unavailable.
  • PMID:20301317 and PMID:20301790 were listed as PS4 candidates but have no fetched abstract/full-text extraction in this case.
Sources
PM3 VCEPNot assessed: no affected-proband, pathogenic-in-trans, phenotype, or phase evidence was available to assign the ATM VCEP's PM3 points. Details ▾Hide ▴
Reasoning

The ATM VCEP defines PM3 for a recessive disorder when the variant under assessment is detected in trans with a pathogenic variant, with strength determined by points assigned per unrelated A-T proband according to phenotype and phase. The case evidence bundle provides no affected-proband observation, A-T phenotype classification, second-variant classification, or phase information for NM_000051.4:c.6248G>C (p.Gly2083Ala/p.G2083A). The governing file ATM_PM3_BP2_1.6.pdf was searched for c.6248G>C, p.Gly2083Ala, and p.G2083A; no variant-specific entry or pre-assigned PM3 code was found. Therefore PM3 cannot be assessed without substituting evidence or a threshold not supplied by the VCEP.

VCEP rule
For recessive disorders, detected in trans with a pathogenic variant
Evidence considered
  • ATM_PM3_BP2_1.6.pdf, pages 1-3: the VCEP PM3 rule requires a recessive-disorder observation in trans with a pathogenic variant and assigns points per unrelated A-T proband based on phenotype and phase.
  • ATM_PM3_BP2_1.6.pdf searched under c.6248G>C, p.Gly2083Ala, and p.G2083A: no matching variant-specific row or pre-assigned PM3 code was found.
  • The case-evidence bundle contains no documented affected A-T proband, phenotype category, pathogenic variant in trans, or phase observation for this variant.
Still missing
  • ATM_PM3_BP2_1.6.pdf was searched for c.6248G>C, p.Gly2083Ala, and p.G2083A; no variant-specific entry or pre-assigned PM3 code was found.
  • No case-specific affected A-T proband, phenotype classification, pathogenic variant in trans, or phase result is documented in the reviewed case-evidence bundle.
Sources
PP1 VCEPNot assessed: no documented affected-relative segregation count or informative meioses is available to meet the VCEP's PP1 thresholds. Details ▾Hide ▴
Reasoning

The ATM VCEP provides PP1 thresholds for autosomal-recessive disease based on segregation in affected relatives: supporting for 1, moderate for 2, and strong for at least 3 affected relatives. The reviewed case evidence contains no documented proband pedigree, affected relative count, parental testing, or informative meioses for NM_000051.4:c.6248G>C, so PP1 cannot be assigned.

VCEP rule
AR Condition: Segregation in ≥3 affected relatives ... AR Condition: Segregation in 2 affected relatives ... AR Condition: Segregation in 1 affected relative
Evidence considered
  • The reviewed case evidence contains no exact-variant family segregation report, affected-relative count, parental testing result, or informative meioses for NM_000051.4:c.6248G>C (ATM p.Gly2083Ala).
  • ClinGen HBOP ATM VCEP v1.6 CSPEC PP1 rules specify supporting for segregation in 1 affected relative, moderate for 2 affected relatives, and strong for at least 3 affected relatives.
Still missing
  • A pedigree with the exact variant, phenotype status, tested relatives, and informative meioses is needed to determine whether segregation occurred in 1, 2, or at least 3 affected relatives.
Sources
BP2 VCEPNot assessed: no unaffected-adult observation, pathogenic co-occurring variant, or cis/trans phase evidence was available to assign the ATM VCEP's BP2 points. Details ▾Hide ▴
Reasoning

The ATM VCEP defines BP2 for observation in trans with a pathogenic variant in a fully penetrant dominant gene/disorder or in cis with a pathogenic variant in any inheritance pattern; its table assigns negative points for an unaffected non-A-T adult proband. The case evidence bundle provides no unaffected adult observation, pathogenic co-occurring variant, or cis/trans phase information for NM_000051.4:c.6248G>C (p.Gly2083Ala/p.G2083A). The governing file ATM_PM3_BP2_1.6.pdf was searched for c.6248G>C, p.Gly2083Ala, and p.G2083A; no variant-specific entry or pre-assigned BP2 code was found. Therefore BP2 cannot be assessed under the VCEP rules.

VCEP rule
Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • ATM_PM3_BP2_1.6.pdf, pages 2-3: the VCEP BP2 rule covers a pathogenic variant in trans for a fully penetrant dominant gene/disorder or a pathogenic variant in cis in any inheritance pattern, with negative points assigned for unaffected non-A-T adult probands.
  • ATM_PM3_BP2_1.6.pdf searched under c.6248G>C, p.Gly2083Ala, and p.G2083A: no matching variant-specific row or pre-assigned BP2 code was found.
  • The case-evidence bundle contains no documented unaffected adult, pathogenic co-occurring variant, or cis/trans phase observation for this variant.
Still missing
  • ATM_PM3_BP2_1.6.pdf was searched for c.6248G>C, p.Gly2083Ala, and p.G2083A; no variant-specific entry or pre-assigned BP2 code was found.
  • No case-specific unaffected adult, pathogenic co-occurring variant, or cis/trans phase result is documented in the reviewed case-evidence bundle.
Sources
Not applicable · 16· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: c.6248G>C is a missense substitution, whereas the VCEP PVS1 rule applies to specified null variants. Details ▾Hide ▴
Reasoning

NM_000051.4:c.6248G>C is a missense variant, p.(Gly2083Ala), in exon 43, not a nonsense, frameshift, canonical splice-site, initiation-codon, or exon-deletion variant. The VCEP PVS1 rule is limited to null variants listed in its governing definition, so PVS1 does not apply. The exact variant notations c.6248G>C, p.Gly2083Ala, and p.G2083A were searched in ATM_PVS1_1.6.pdf.txt; no pre-assigned entry for this variant was found.

VCEP rule
Null variant (nonsense, frameshift, canonical +/-1 or 2 splice sites, initiation codon, single or multi-exon deletion) in a gene where loss of function (LOF) is a known mechanism of disease
Evidence considered
  • Case variant facts: NM_000051.4:c.6248G>C; NP_000042.3:p.(Gly2083Ala), p.(G2083A); exon 43; consequence class missense.
  • ClinGen HBOP ATM VCEP PVS1 decision guide: the governing PVS1 definition covers null variants, including nonsense, frameshift, canonical +/-1 or 2 splice sites, initiation codon, and single or multi-exon deletion; the requested missense variant is outside those named types.
  • ATM_PVS1_1.6.pdf.txt was searched for c.6248G>C, p.Gly2083Ala, and p.G2083A; no pre-assigned row or entry for this variant was found.
Still missing
  • ATM_PVS1_1.6.pdf.txt was searched for c.6248G>C, p.Gly2083Ala, and p.G2083A; no exact variant entry was found.
Sources
PS2 VCEPNot applicable: the ATM VCEP specification explicitly marks PS2 as not applicable. Details ▾Hide ▴
Reasoning

The ATM VCEP specification marks PS2 as not applicable. No de novo evidence is used.

VCEP rule
Not Applicable
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 CSPEC entry for PS2: applicability is "Not Applicable".
Sources
PM1 VCEPNot applicable: the ATM VCEP prohibits PM1 because benign and pathogenic variants occur in the same domains and hotspots are not well defined. Details ▾Hide ▴
Reasoning

PM1 is not applicable under the ATM VCEP. The VCEP explicitly instructs reviewers not to use PM1 because benign and pathogenic variants are known within the same domains and germline mutational hotspots are not well defined. The case vcep_materials.json domain_tables object has no ATM entry, and the VCEP's direct applicability instruction independently bars this criterion.

VCEP rule
Do not use: Benign and pathogenic variants are known to occur within the same domains and germline mutational hotspots are not well defined at this time
Evidence considered
  • ATM VCEP PM1 applicability instruction: Do not use because benign and pathogenic variants are known to occur within the same domains and germline mutational hotspots are not well defined.
  • vcep_materials.json: domain_tables is empty for ATM.
Sources
PM4 N/ANot applicable: p.(Gly2083Ala) is a missense substitution with no stop-loss consequence, the sole variant type allowed by the VCEP PM4 rule. Details ▾Hide ▴
Reasoning

NM_000051.4:c.6248G>C produces the missense substitution p.(Gly2083Ala), with no protein-length change, in-frame insertion/deletion, or stop-loss consequence. The ATM VCEP PM4 rule is restricted to stop-loss variants, so PM4 is not applicable.

VCEP rule
Use for stop-loss variants.
Evidence considered
  • Case variant facts: NM_000051.4:c.6248G>C; NP_000042.3:p.(Gly2083Ala); consequence class missense.
  • ClinGen HBOP ATM VCEP PM4 entry: the criterion is to be used for stop-loss variants only; this missense substitution does not create a stop-loss or protein-length change.
Sources
PM5 N/ANot applicable: the ATM VCEP explicitly excludes missense changes from PM5, regardless of same-residue comparator evidence. Details ▾Hide ▴
Reasoning

PM5 is not applicable to this missense variant under the ATM VCEP. Although the VCEP's PM5 entry is applicable for specified truncating variants upstream of p.Leu3048, its instructions explicitly state not to use PM5 for missense changes because multiple amino-acid substitutions at the same residue can be pathogenic or benign and cannot be confidently distinguished by bioinformatic tools.

VCEP rule
Do not use for missense changes: Multiple amino acid substitutions at the same residue can be pathogenic or benign and bioinformatic tools cannot yet confidently distinguish them
Evidence considered
  • ATM VCEP PM5 instructions: use PM5 Supporting for the specified NMD-prone truncating framework, but do not use it for missense changes.
Sources
PM6 VCEPNot applicable: the ATM VCEP specification explicitly marks PM6 as not applicable. Details ▾Hide ▴
Reasoning

The ATM VCEP specification marks PM6 as not applicable. No assumed de novo evidence is used.

VCEP rule
Not Applicable
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 CSPEC entry for PM6: applicability is "Not Applicable".
Sources
PP2 VCEPNot applicable: the ATM VCEP states that ATM lacks a defined low rate of benign missense variation. Details ▾Hide ▴
Reasoning

PP2 is not applicable under the ATM VCEP. The VCEP states that ATM does not have a defined low rate of benign missense variation, so the gene-level PP2 criterion must not be used.

VCEP rule
Do not use: ATM does not have a defined low rate of missense benign variation.
Evidence considered
  • ATM VCEP PP2 applicability instruction: Do not use because ATM does not have a defined low rate of benign missense variation.
Sources
PP4 VCEPNot applicable: the ATM VCEP excludes PP4 for hereditary breast cancer and directs ataxia-telangiectasia phenotype evidence into PM3/BP2. Details ▾Hide ▴
Reasoning

The ATM VCEP states that PP4 is not applicable for either relevant disease context: it should not be used for autosomal-dominant breast cancer because of genetic heterogeneity, and it should not be used separately for autosomal-recessive ataxia-telangiectasia because phenotype evidence is incorporated into the PM3/BP2 table.

VCEP rule
Autosomal Dominant: do not use as breast cancer is a disease with multiple genetic etiology (genetic heterogeneity) and there are no features that can readily distinguish hereditary from sporadic causes. Autosomal Recessive: do not use as a separate line of evidence. Such evidence is built into the Ataxia Telangiectasia PM3|BP2 table
Evidence considered
  • ATM VCEP v1.6 PP4 instructions: Autosomal Dominant: do not use as breast cancer is a disease with multiple genetic etiology (genetic heterogeneity) and there are no features that can readily distinguish hereditary from sporadic causes.
  • ATM VCEP v1.6 PP4 instructions: Autosomal Recessive: do not use as a separate line of evidence. Such evidence is built into the Ataxia Telangiectasia PM3|BP2 table.
Sources
PP5 VCEPNot applicable: the ATM VCEP explicitly prohibits use of PP5. Details ▾Hide ▴
Reasoning

The ATM VCEP marks PP5 as not applicable and explicitly states that this criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.

VCEP rule
This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
Evidence considered
  • ATM VCEP v1.6 PP5 instructions: This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
Sources
BS2 VCEPNot applicable: the ATM VCEP excludes BS2 because ATM has incomplete penetrance, regardless of healthy-individual or homozygote observations. Details ▾Hide ▴
Reasoning

The ATM VCEP marks BS2 as not applicable and explicitly instructs: "Do not use: ATM has incomplete penetrance." No healthy-individual or homozygote evidence can override that governing applicability decision.

VCEP rule
Do not use: ATM has incomplete penetrance.
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 BS2 instruction: Do not use: ATM has incomplete penetrance.
Sources
BS4 VCEPNot applicable: the ATM VCEP specification explicitly marks BS4 as not applicable. Details ▾Hide ▴
Reasoning

The ATM VCEP specification marks BS4 as not applicable. No non-segregation evidence is used.

VCEP rule
Not Applicable
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 CSPEC entry for BS4: applicability is "Not Applicable".
Sources
BP1 VCEPNot applicable: missense pathogenic variants are known for ATM, so the ATM VCEP excludes BP1. Details ▾Hide ▴
Reasoning

BP1 is not applicable under the ATM VCEP. The VCEP states that missense pathogenic variants are known for ATM, so BP1 cannot be used for this missense variant.

VCEP rule
Do not use: Missense pathogenic variants are known for ATM
Evidence considered
  • ATM VCEP BP1 applicability instruction: Do not use because missense pathogenic variants are known for ATM.
Sources
BP3 VCEPNot applicable: the VCEP marks BP3 not applicable, and this variant is missense rather than an in-frame deletion or insertion. Details ▾Hide ▴
Reasoning

NM_000051.4:c.6248G>C is a missense substitution, p.(Gly2083Ala), rather than an in-frame deletion or insertion. The ATM VCEP explicitly marks BP3 as not applicable and instructs curators not to use it; repeat-region context therefore cannot activate this criterion.

VCEP rule
Do not use.
Evidence considered
  • Case variant facts: NM_000051.4:c.6248G>C; NP_000042.3:p.(Gly2083Ala); consequence class missense.
  • ClinGen HBOP ATM VCEP BP3 entry: applicability is not applicable and the instructions state "Do not use." The original ACMG description concerns in-frame deletions/insertions in repetitive regions, which is not the consequence here.
Sources
BP5 VCEPNot applicable: the ATM VCEP instructs reviewers not to use BP5 because ATM has low penetrance and frequent pathogenic-variant co-occurrence. Details ▾Hide ▴
Reasoning

The ATM VCEP marks BP5 as not applicable and instructs that it should not be used because cases with multiple pathogenic variants have been observed without a noticeable phenotype difference; ATM's low penetrance also makes co-occurrence with other pathogenic variants more frequent.

VCEP rule
Do not use: Cases with multiple pathogenic variants have been observed with no noticeable difference in phenotype (e.g. BRCA1 and BRCA2). In addition, ATM has low penetrance and will naturally occur with other pathogenic variants more frequently due to higher tolerance/presence in the general population.
Evidence considered
  • ATM VCEP v1.6 BP5 instructions: Do not use: Cases with multiple pathogenic variants have been observed with no noticeable difference in phenotype (e.g. BRCA1 and BRCA2). In addition, ATM has low penetrance and will naturally occur with other pathogenic variants more frequently due to higher tolerance/presence in the general population.
Sources
BP6 VCEPNot applicable: the ATM VCEP explicitly prohibits use of BP6. Details ▾Hide ▴
Reasoning

The ATM VCEP marks BP6 as not applicable and explicitly states that this criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.

VCEP rule
This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
Evidence considered
  • ATM VCEP v1.6 BP6 instructions: This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
Sources
BP7 N/ANot applicable: BP7 is limited to synonymous or deep intronic variants, but this variant is missense. Details ▾Hide ▴
Reasoning

The variant is missense, whereas the ATM VCEP BP7 rule applies to synonymous and deep intronic variants, or to observed RNA evidence for silent and intronic variants. BP7 is therefore outside its governing scope.

VCEP rule
* BP7: Use for synonymous and deep intronic variants defined as further than (but not including) +7 and further than (but not including) -21 at donor and acceptor sites, respectively. * BP7(RNA): Observed lack of aberrant RNA defect for silent substitutions and intronic variants. Variable weight applied depending on curator discretion of assay quality.
Evidence considered
  • Case variant assessment: NM_000051.4:c.6248G>C encodes NP_000042.3:p.(Gly2083Ala) and is classified as missense in exon 43.
Sources

Identifiers

Gene
ATM
Transcript
NM_000051.4
Coding (HGVS c.)
NM_000051.4:c.6248G>C
Protein (HGVS p.)
NP_000042.3:p.(Gly2083Ala)
GRCh38
chr11:108317422 G>C
GRCh37
chr11:108188149 G>C
Location and type
Exon 43 · missense
ClinVar
826265
COSMIC
COSV53733578

Gene diagram

Every interpreted variant in ATM, mapped onto the exon structure of NM_000051.4. Select a row to find it on the plot.

ATMNM_000051.4
Fetching transcript structure from UCSC…
gnomAD v4.1 4 / 1,612,182 alleles AF 2.48e-06 · 0 homozygotes · FAF 6.8e-07
gnomAD v2.1 Allele count data not recorded
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 2.5e-06 · 4 / 1,612,182 alleles · 0 hom · FAF 6.8e-07
Remaining individuals1 / 62,406 1.6e-05
European (non-Finnish)3 / 1,179,168 2.5e-06
0 alternate alleles recorded in 8 other groups: Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American.

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 2.48111e-06; MAF= 0.00025%, 4/1612182 alleles, homozygotes = 0) and has highest observed frequency in the Remaining individuals population (AF= 1.60241e-05; MAF= 0.00160%, 1/62406 alleles, homozygotes = 0); grpmax FAF= 6.8e-07.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat +0 bp
0.463
SpliceAI acceptor gainat -40 bp
0.075
SpliceAI donor lossat -130 bp
0.000
SpliceAI donor gainat +99 bp
0.000
Pangolin splice lossmagnitude shown
-0.234
Pangolin splice gain
0.036

Other predictors

REVEL
0.295
BayesDel
-0.291

How the predictions were used

PP3 SupportingVCEPMet: SpliceAI max delta 0.463 meets the ATM VCEP PP3 threshold of >=0.2 for predicted splice impact in missense variants. Details ▾Hide ▴
Reasoning

The variant is missense. The ATM VCEP PP3 rule permits either missense REVEL >.7333 or predicted splice impact by SpliceAI >=0.2 for missense variants. REVEL is 0.295 and therefore does not meet the missense path, but SpliceAI max delta is 0.463, which meets the VCEP splicing path. PP3 is met at Supporting strength from the splice prediction; the same SpliceAI result is not used to claim BP4 or BP7.

VCEP rule
* Missense: REVEL **>.7333** * Splicing: Predicted impact via splicing (SpliceAI **≥0.2**) for silent, missense/in-frame and for intronic variants outside of donor and acceptor 1,2 sites.
Evidence considered
  • SpliceAI Lookup for NM_000051.4:c.6248G>C: DS_AG=0.075, DS_AL=0.463, DS_DG=0.0, DS_DL=0.0; max delta score=0.463.
  • Local REVEL predictor lookup for NM_000051.4:c.6248G>C: REVEL=0.295, below the VCEP PP3 missense cutoff >.7333.
  • Sun et al. 2025 Supplementary Table S1, exact row ATM c.6248G>C / G2083A: missense; REVEL=0.295; Classification=Functional; Confidence=High; DeepATM_predicted=No. This table was consulted as the governing VCEP reference file, while the PP3 decision uses the VCEP-named REVEL and SpliceAI paths.
Sources
BP4 VCEPNot met: REVEL 0.295 exceeds the <=0.249 BP4 cutoff and SpliceAI max delta 0.463 exceeds the <=0.1 no-impact cutoff. Details ▾Hide ▴
Reasoning

The variant is missense. The ATM VCEP BP4 rule permits REVEL <=.249 or no predicted splice impact by SpliceAI <=0.1. REVEL is 0.295, above the missense cutoff, and SpliceAI max delta is 0.463, above the no-impact cutoff. Neither VCEP BP4 path is met.

VCEP rule
* Missense: REVEL score **≤.249** * Splicing: No predicted impact via splicing (SpliceAI **≤0.1**).
Evidence considered
  • Local REVEL predictor lookup for NM_000051.4:c.6248G>C: REVEL=0.295, which is above the ATM VCEP BP4 missense threshold of <=.249.
  • SpliceAI Lookup for NM_000051.4:c.6248G>C: max delta score=0.463, which is above the ATM VCEP BP4 no-predicted-impact threshold of <=0.1.
  • Sun et al. 2025 Supplementary Table S1, exact row ATM c.6248G>C / G2083A: missense; REVEL=0.295; Classification=Functional; Confidence=High; DeepATM_predicted=No.
Sources
BP7 N/ANot applicable: BP7 is limited to synonymous or deep intronic variants, but this variant is missense. Details ▾Hide ▴
Reasoning

The variant is missense, whereas the ATM VCEP BP7 rule applies to synonymous and deep intronic variants, or to observed RNA evidence for silent and intronic variants. BP7 is therefore outside its governing scope.

VCEP rule
* BP7: Use for synonymous and deep intronic variants defined as further than (but not including) +7 and further than (but not including) -21 at donor and acceptor sites, respectively. * BP7(RNA): Observed lack of aberrant RNA defect for silent substitutions and intronic variants. Variable weight applied depending on curator discretion of assay quality.
Evidence considered
  • Case variant assessment: NM_000051.4:c.6248G>C encodes NP_000042.3:p.(Gly2083Ala) and is classified as missense in exon 43.
Sources

Statement

In silico

SpliceAI predicts possible splice impact for this variant (max delta score = 0.46). REVEL score = 0.295. BayesDel score = -0.291348.

9 paper records listed. 1 cited in the classification. None of the listed paper records explicitly indicates that the variant is named.

Cited in the classification

  • Sun et al. 2025
    Sun et al. 2025 Supplementary Table S1 reports the exact ATM variant c.6248G>C / G2083A in exon 43 as Missense, with Classification=Functional, Confidence=High, and DeepATM_predicted=No. Under the governing VCEP file rule, this is a direct prime-editing measurement and supports BS3_Supporting; it does not support PS3.
    → BS3 · supporting Names this variant
    PMID 40580951 ↗
    Source detail
    108317422 G C c.6248G>C G2083A exon_43 11 Missense 2083 26.9 0.8582293 0.789613274001145 0.295 0.2338 2.73848433107e-06 Uncertain significance -0.814746416276098 Functional High No

    Location Supplementary Table S1, exact row c.6248G>C / G2083A

    Context Sun et al. 2025 functional assessment of ATM SNVs using prime editing and deep learning; the exact row has DeepATM_predicted=No and Confidence=High, so the VCEP file rule treats the Classification as a direct prime-editing measurement.

Other recorded publications

  • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
    Richards S et al. · 2015
    No paper-specific finding is recorded.
    PMID 25741868 ↗
  • A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders.
    Karbassi I et al. · 2016
    No paper-specific finding is recorded.
    PMID 26467025 ↗
  • Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks.
    Decker B et al. · 2017
    The paper reports a population-based case-control sequencing study of ATM, CHEK2, PALB2, and XRCC2 involving 13,087 breast cancer cases and 5,488 controls. Aggregate rare ATM missense variants had OR=1.18 (95% CI 0.99–1.40; p=0.073), but the requested variant is not mentioned.
    Does not name this variant
    PMID 28779002 ↗
    Quoted passage
    We found some evidence of increased BC risk associated with the combined rare missense substitutions in ATM (OR=1.18; 95% CI 0.99 to 1.40, p=0.073), CHEK2 (OR=1.36; 95% CI 0.99 to 1.87, p=0.066) and PALB2 (OR=1.28; 95% CI 0.95 to 1.73, p=0.12), but not in XRCC2.

    Results, Risk associations for subsets of missense variants

  • Hereditary Ataxia Overview.
    Adam MP et al. · 1993
    This PMID was listed as a PS4/PP5 candidate in literature_pass.json, but no fetched abstract or full-text extraction is available in this case, so variant-specific verification could not be performed.
    Does not name this variant
    PMID 20301317 ↗
  • Ataxia-Telangiectasia.
    Adam MP et al. · 1993
    This PMID was listed as a PS4/PP5 candidate in literature_pass.json, but no fetched abstract or full-text extraction is available in this case, so variant-specific verification could not be performed.
    Does not name this variant
    PMID 20301790 ↗
  • EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood.
    van de Warrenburg BP et al. · 2014
    This consensus guideline discusses ataxia-telangiectasia generally but does not mention ATM c.6248G>C or p.Gly2083Ala and provides no variant-specific case-control data.
    Does not name this variant
    PMID 24418350 ↗
    Quoted passage
    The second most frequent recessive ataxia globally is ataxia telangiectasia, with the exception of North Africa where this is ataxia with vitamin E deficiency [15,16].

    Recessive family history

  • A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.
    Hampel H et al. · 2015
    The paper does not mention ATM c.6248G>C or p.Gly2083Ala and provides no variant-specific clinical or case-control evidence.
    Does not name this variant
    PMID 25394175 ↗
  • Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.
    Breast Cancer Association Consortium et al. · 2021
    The paper reports aggregate associations for rare ATM missense variants in 60,466 women with breast cancer and 53,461 controls. Population-based studies showed OR=1.06 (95% CI 1.00–1.13; P=0.051); the requested variant is not mentioned.
    Does not name this variant
    PMID 33471991 ↗
    Quoted passage
    For ATM, there was an increased risk associated with variants in the FRAP-ATM-TRRAP (FAT) domain

    Results, Rare Missense Variants; Table 2; Tables S13 and S16; Figure S1C

  • EFNS guidelines on the molecular diagnosis of ataxias and spastic paraplegias.
    Gasser T et al. · 2010
    No paper-specific finding is recorded.
    PMID 20050888 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 2.48111e-06; MAF= 0.00025%, 4/1612182 alleles, homozygotes = 0) and has highest observed frequency in the Remaining individuals population (AF= 1.60241e-05; MAF= 0.00160%, 1/62406 alleles, homozygotes = 0); grpmax FAF= 6.8e-07.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant has been reported in ClinVar as Uncertain significance (5 clinical laboratories). (ClinVarID = 826265)

In silico

SpliceAI predicts possible splice impact for this variant (max delta score = 0.46). REVEL score = 0.295. BayesDel score = -0.291348.

Functional

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. ATM, a kinase involved in the DNA damage response, is mutated in various solid and hematologic malignancies.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV53733578, n = 1 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.